TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on June 18, 2018. The report discloses "Other Events" (Item 8.01) related to the oral presentation of clinical data for two of the Company's investigational drug candidates at major medical conferences.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or performance metrics.
Material Changes and Clinical Updates
- Umbralisib (TGR-1202): The Company presented data from an ongoing Phase 2 study evaluating this PI3K delta inhibitor in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy. The presentation occurred at the 23rd Congress of the European Hematology Association (EHA).
- Ublituximab (TG-1101): The Company announced updated results from a Phase 2 multicenter trial of this novel glycoengineered anti-CD20 monoclonal antibody in relapsing forms of Multiple Sclerosis (RMS). The announcement was made at the 4th Congress of the European Academy of Neurology (EAN) in Lisbon, Portugal.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future financial performance, or a discussion of risks and contingencies beyond the context of the clinical data presentations. The primary purpose of the filing is to disseminate the clinical updates referenced in the attached press releases (Exhibits 99.1 and 99.2).
Key Facts for Investor Verification
- Verify the specific efficacy and safety data points for umbralisib in the CLL patient population by reviewing the full press release (Exhibit 99.1).
- Review the updated statistical results for ublituximab in RMS patients as detailed in the press release (Exhibit 99.2).
- Confirm the regulatory status and next steps for both drug candidates following these conference presentations.